期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 84, 期 4, 页码 1457-1460出版社
IOS PRESS
DOI: 10.3233/JAD-215275
关键词
Aducanumab; aduhelm; Alzheimer's disease; amyloid PET; dementia
This article discusses the mechanism of action of the FDA-approved anti-Alzheimer drug and the authors' view on the role of amyloid deposits in the progression of the disease.
According to the FDA, aducanumab (Aduhelm), the recently approved anti-Alzheimer drug, reduces the level of cerebral amyloid plaques-a hallmark finding in patients with Alzheimer's disease-and this will result in a reduction in clinical decline. The authors of this article are not convinced that amyloid deposits are a hallmark of Alzheimer's disease and are of the opinion that the apparent reduction in amyloid accumulation following aducanumab treatment is likely instead a result of continued and advanced cerebral cell death and, thus, not a sign of improvement but of an even more advanced disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据